The bleeding disorders community reminds me of that massive oak tree.

Mumbai: Sanofi Consumer Healthcare India Limited has announced the upcoming departure of two of its senior leaders.Maithilee ...

The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the third time. In September, J&J, via a subsidiary called Red River Talc, filed ...

This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...

Sanofi's oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib has gained US Food and Drug Administration ...

Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response ...